| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Outline of Final Research Achievements |
185 patients with epilepsy (PWE) answered a self-evaluation questionnaire containing items affecting quality of life (QOL): 1) QOL, 2) psychology and mental condition, 3) expression ability to others, 4) understanding ability, 5) underestimation and 6) overestimation by others, and restrictions due to 7) seizures and 8) antiepileptic drugs (AEDs). We examined their clinical seizure status (frequency, disease duration, number of AEDs) and psycho-behavioral rating scale scores (BDI-II, AQ, CAARS, WAIS-III). We found significant correlations between QOL question item (1-6) and many items of the BDI-II, AQ, and CAARS. However, we found no significant correlations between each questionnaire item and seizure status except for item (7) and clinical seizure frequency. CAARS-A, C, D scales correlated with most questionnaire items, but CAARS-B scale correlated with only two items (3, 4). We found no significant correlations between each questionnaire item and each WAIS-III item.
|
| Academic Significance and Societal Importance of the Research Achievements |
てんかん患者の主観的または社会適応上の問題が標準的な高次脳検査では十分に評価できないことが臨床的にしばしば遭遇する。本研究の目的は心理検査・精神医学的検査を多面的に組み合わせた心理バッテリーからてんかん患者の実生活上困難となる社会認知的問題を定性的・定量的に具体性をもって測定する方法を開発することにあった。てんかん患者ではAQ,BDI-II,CAARSといった精神・行動の評価スケールの得点が発作状態以上に主観的な自己評価と幅広く相関し、これらの評価を行うことで今まで十分に評価されて来なかったてんかん患者の生活の質を低下させる要因に光を当てることには意義があると考えられた。
|
